Chronic Atrial FibrillationExerciseNCT01892774
Impact of the Pulmonary Vein Isolation on Exercise Capacity in Patients With Chronic Atrial Fibrillation
An observational study of Chronic Atrial Fibrillation, run by Texas Cardiac Arrhythmia Research Foundation at 1 site in United States.
Trial summary
This study would assess the impact of radio-frequency catheter ablation on exercise capacity and quality of life in long-standing persistent atrial fibrillation (LSP-AF) patients Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Chronic Atrial Fibrillation
- What is being tested?
- Radiofrequency catheter ablation
- Type of treatment
- Surgery or procedure
- How many people
- 150 participants
- Where
- 1 siteUnited States
- Study dates
- Jan 2010to Dec 2019
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Chronic asymptomatic long-standing persistent AF
Who may be able to join
- Asymptomatic LSP-AF patients undergoing first catheter ablation
- > 18-80 years
- Ability to give consent
Who cannot join
- Low LVEF
- Inability to comply with follow-up testing
Trial locations and contacts
1 site in 1 country.
United States1 site
Texas Cardiac Arrhythmia Institute, St. david's Medical Center
Austin, Texas, 78705
About this study
This study would assess the impact of radio-frequency catheter ablation on exercise capacity and quality of life in long-standing persistent atrial fibrillation (LSP-AF) patients
Read the detailed description
III. Goals of the Project The purpose of this study is to determine whether pulmonary vein isolation with radiofrequency ablation will improve exercise capacity and endothelial function in patients with chronic atrial fibrillation. We hypothesize that exercise capacity and endothelial function will improve in patients with chronic atrial fibrillation following pulmonary vein isolation.
IV. Background and Significance:
Easy fatigability is a frequent complaint in patients with atrial fibrillation (AF). Prior studies have demonstrated that exercise capacity in patients with "lone atrial fibrillation" is less than that in healthy matched controls. Other investigators have also shown the adverse effect of AF by comparing peak oxygen uptake VO2 prior to and after cardioversion. At present, the majority of studies have focused on patients in whom with AF with either mild cardiovascular disease or congestive failure. No study to date has assessed if pulmonary vein isolation (PVI) via intracardiac ablation is able to improve exercise capacity in patients with chronic LSP-AF.
This prospective registry will assess exercise capacity in patients with chronic AF (CAF) over a minimum period of 3 months; prior to and after PVI. Chronic AF is defined as those patients who have an unsuccessful cardioversion and/or an ongoing AF episode (e.g. a year or more). The observed results will be used to establish a better understanding of overall quality of life and exercise tolerance prior to and after ablation. This registry may be further expanded in the future and in a second study to assess exercise tolerance in patients with CAF who have been treated with alternative treatment strategies. The findings from this study may begin to pave the way for future clinical practice changes to best manage patients with CAF.
Description of the procedures: Patients will be required to fast and refrain from smoking at least 4 hours prior to each testing session.
Arterial Stiffness Arterial stiffness will be measured non-invasively. Two indices of arterial stiffness will be calculated including carotid augmentation index and aortic pulse wave velocity after the subject has assumed the supine position for at least 10 minutes. Blood pressure cuffs will be placed on both arms and legs, and ECG sensors will be placed on both wrists. Carotid augmentation index will be calculated as the ratio of the amplitude of the pressure wave above its systolic shoulder to the total pulse pressure. Aortic pulse wave velocity will be calculated by dividing the distance (carotid to femoral artery) by the transit time (time delay between the carotid and femoral "foot" waveforms).
Endothelial Health The VENDYS 5000 BCTM (Endothelix, Houston, TX) is an FDA approved device that will be used to measure vascular responsiveness, which is an index of endothelial function. It measures changes in skin temperature of the fingertip in response to changes in blood flow in the arm induced by a 5-minute cuff occlusion, and provides information about vascular health.
The subjects will be seated for this test with a cuff fixed around the upper right arm and VENDYS probes on the index fingers of both hands. Fingertip temperatures will be measured throughout the procedure until 3 minutes after deflation of the cuff. Baseline fingertip temperature will be measured for 3 minutes before cuff inflation. Following baseline measures, the cuff will rapidly inflate to 200 mmHg or 50 mmHg above resting systolic blood pressure and will remain inflated for 5 minutes. During this time, the fingertip temperature will fall due to the occlusion of blood flow. After 5 minutes, the cuff will rapidly deflate allowing blood flow to return to the arm. Skin temperature will be measured constantly for 3 minutes.
Exercise Capacity Subjects will perform a modified version of the Balke2 incremental treadmill exercise test. The test begins with a 0% grade at a constant speed of 3.0 mph. The grade will be increased by 1% every minute while the speed remains constant. Oxygen consumption, heart rate, and ratings and perceived exertion (Borg Scale) will be measured throughout the test and total exercise time to exhaustion will be recorded. Oxygen consumption will be measured with a metabolic cart while the subjects breathe through a mouth piece. Blood pressures and ECG will be monitored continuously.
Quality of Life Assessment The MOS 36-short form is a multi-purpose, short-form health survey with only 36 questions. It yields an 8-scale profile of functional health and well-being scores as well as psychometrically-based physical and mental health summary measures and a preference-based health utility index. It is a generic measure, as opposed to one that targets a specific age, disease, or treatment group. Accordingly, the MOS-36 has proven useful in surveys of general and specific populations, comparing the relative burden of diseases, and in differentiating the health benefits produced by a wide range of different treatments.
- Conditions
- Chronic Atrial Fibrillation
- Being tested
- Radiofrequency catheter ablation
- Keywords
- LSPAF, asymptomatic, exercise tolerance
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Radiofrequency catheter ablationProcedure or surgery
Also called Extended PVAI plus ablation of non-PV triggers and CAFE
Extended PVAI plus ablation of non-pulmonary vein (non-PV) triggers and complex fractionated electrograms (CAFÉ)
What is being measured
The primary outcome is the main question the study is designed to answer.
Improvement in exercise capacity and/or endothelial health
Improvement in exercise tolerance and endothelial health as measured by Vmax Encore and Vendys 5000 BC equipment
Measured: 5-6 months following catheter ablation
Secondary outcomes (2)
Improvement in quality of life (QoL)
Improvement in QoL as measured by SF-36 scale
Measured: 1 year following catheter ablation
Freedom from arrhythmia recurrence
Arrhythmia free survival as assessed by cardiology evaluations
Measured: 1 year post-ablation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Jul 2013 (estimated)
- Study startJan 2010
- Primary completionDec 2018
- Study completionDec 2019 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Chronic Atrial FibrillationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 150 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Texas Cardiac Arrhythmia Research Foundation
- Sponsor type
- University, hospital or other
- Collaborators
- University of Texas at Austin
- Responsible party
- Sponsor
- Investigators
- Andrea Natale, MD, Principal investigator, TCAI
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01892774
- Sponsor's protocol ID
- TCAI_Exercise
- Acronym
- Exercise
- Status last verified
- Apr 2019
- First submitted
- 1 Jul 2013
- Last updated
- 10 Apr 2019
- Results posted
- No
- Data monitoring committee
- No
Publications
Mohanty S, Santangeli P, Mohanty P, Di Biase L, Holcomb S, Trivedi C, Bai R, Burkhardt D, Hongo R, Hao S, Beheiry S, Santoro F, Forleo G, Gallinghouse JG, Horton R, Sanchez JE, Bailey S, Hranitzky PM, Zagrodzky J, Natale A. Catheter ablation of asymptomatic longstanding persistent atrial fibrillation: impact on quality of life, exercise performance, arrhythmia perception, and arrhythmia-free survival. J Cardiovasc Electrophysiol. 2014 Oct;25(10):1057-64. doi: 10.1111/jce.12467. Epub 2014 Jul 7.
PubMed 24903064
Study at a glance
From the registry record, last updated by the sponsor on 10 Apr 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact of the Pulmonary Vein Isolation on Exercise Capacity in Patients With Chronic Atrial Fibrillation
- ClinicalTrials.gov ID
- NCT01892774
- Acronym / sponsor ID
- Exercise / TCAI_Exercise
- Conditions
- Chronic Atrial Fibrillation
- Keywords
- LSPAF, asymptomatic, exercise tolerance
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 150 participants (estimated)
- Lead sponsor
- Texas Cardiac Arrhythmia Research FoundationUniversity, hospital or other
- Collaborators
- University of Texas at Austin
- Study start
- Jan 2010
- Primary completion
- Dec 2018 (actual)
- Study completion
- Dec 2019 (estimated)
- First posted
- 4 Jul 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study would assess the impact of radio-frequency catheter ablation on exercise capacity and quality of life in long-standing persistent atrial fibrillation (LSP-AF) patients
Detailed description
III. Goals of the Project The purpose of this study is to determine whether pulmonary vein isolation with radiofrequency ablation will improve exercise capacity and endothelial function in patients with chronic atrial fibrillation. We hypothesize that exercise capacity and endothelial function will improve in patients with chronic atrial fibrillation following pulmonary vein isolation.
IV. Background and Significance:
Easy fatigability is a frequent complaint in patients with atrial fibrillation (AF). Prior studies have demonstrated that exercise capacity in patients with "lone atrial fibrillation" is less than that in healthy matched controls. Other investigators have also shown the adverse effect of AF by comparing peak oxygen uptake VO2 prior to and after cardioversion. At present, the majority of studies have focused on patients in whom with AF with either mild cardiovascular disease or congestive failure. No study to date has assessed if pulmonary vein isolation (PVI) via intracardiac ablation is able to improve exercise capacity in patients with chronic LSP-AF.
This prospective registry will assess exercise capacity in patients with chronic AF (CAF) over a minimum period of 3 months; prior to and after PVI. Chronic AF is defined as those patients who have an unsuccessful cardioversion and/or an ongoing AF episode (e.g. a year or more). The observed results will be used to establish a better understanding of overall quality of life and exercise tolerance prior to and after ablation. This registry may be further expanded in the future and in a second study to assess exercise tolerance in patients with CAF who have been treated with alternative treatment strategies. The findings from this study may begin to pave the way for future clinical practice changes to best manage patients with CAF.
Description of the procedures: Patients will be required to fast and refrain from smoking at least 4 hours prior to each testing session.
Arterial Stiffness Arterial stiffness will be measured non-invasively. Two indices of arterial stiffness will be calculated including carotid augmentation index and aortic pulse wave velocity after the subject has assumed the supine position for at least 10 minutes. Blood pressure cuffs will be placed on both arms and legs, and ECG sensors will be placed on both wrists. Carotid augmentation index will be calculated as the ratio of the amplitude of the pressure wave above its systolic shoulder to the total pulse pressure. Aortic pulse wave velocity will be calculated by dividing the distance (carotid to femoral artery) by the transit time (time delay between the carotid and femoral "foot" waveforms).
Endothelial Health The VENDYS 5000 BCTM (Endothelix, Houston, TX) is an FDA approved device that will be used to measure vascular responsiveness, which is an index of endothelial function. It measures changes in skin temperature of the fingertip in response to changes in blood flow in the arm induced by a 5-minute cuff occlusion, and provides information about vascular health.
The subjects will be seated for this test with a cuff fixed around the upper right arm and VENDYS probes on the index fingers of both hands. Fingertip temperatures will be measured throughout the procedure until 3 minutes after deflation of the cuff. Baseline fingertip temperature will be measured for 3 minutes before cuff inflation. Following baseline measures, the cuff will rapidly inflate to 200 mmHg or 50 mmHg above resting systolic blood pressure and will remain inflated for 5 minutes. During this time, the fingertip temperature will fall due to the occlusion of blood flow. After 5 minutes, the cuff will rapidly deflate allowing blood flow to return to the arm. Skin temperature will be measured constantly for 3 minutes.
Exercise Capacity Subjects will perform a modified version of the Balke2 incremental treadmill exercise test. The test begins with a 0% grade at a constant speed of 3.0 mph. The grade will be increased by 1% every minute while the speed remains constant. Oxygen consumption, heart rate, and ratings and perceived exertion (Borg Scale) will be measured throughout the test and total exercise time to exhaustion will be recorded. Oxygen consumption will be measured with a metabolic cart while the subjects breathe through a mouth piece. Blood pressures and ECG will be monitored continuously.
Quality of Life Assessment The MOS 36-short form is a multi-purpose, short-form health survey with only 36 questions. It yields an 8-scale profile of functional health and well-being scores as well as psychometrically-based physical and mental health summary measures and a preference-based health utility index. It is a generic measure, as opposed to one that targets a specific age, disease, or treatment group. Accordingly, the MOS-36 has proven useful in surveys of general and specific populations, comparing the relative burden of diseases, and in differentiating the health benefits produced by a wide range of different treatments.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Chronic asymptomatic long-standing persistent AF
Key inclusion criteria (3 listed)
- Asymptomatic LSP-AF patients undergoing first catheter ablation
- > 18-80 years
- Ability to give consent
Key exclusion criteria (2 listed)
- Low LVEF
- Inability to comply with follow-up testing
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Radiofrequency catheter ablationAlso: Extended PVAI plus ablation of non-PV triggers and CAFEExtended PVAI plus ablation of non-pulmonary vein (non-PV) triggers and complex fractionated electrograms (CAFÉ) | Procedure or surgery | – |
Primary outcome
Improvement in exercise capacity and/or endothelial health
Time frame: 5-6 months following catheter ablation
Improvement in exercise tolerance and endothelial health as measured by Vmax Encore and Vendys 5000 BC equipment
2 secondary outcomes
Improvement in quality of life (QoL)
Time frame: 1 year following catheter ablation
Freedom from arrhythmia recurrence
Time frame: 1 year post-ablation
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Apr 2019.
- Derived from this study: PubMed 24903064Mohanty S, Santangeli P, Mohanty P, Di Biase L, Holcomb S, Trivedi C, Bai R, Burkhardt D, Hongo R, Hao S, Beheiry S, Santoro F, Forleo G, Gallinghouse JG, Horton R, Sanchez JE, Bailey S, Hranitzky PM, Zagrodzky J, Natale A. Catheter ablation of asymptomatic longstanding persistent atrial fibrillation: impact on quality of life, exercise performance, arrhythmia perception, and arrhythmia-free survival. J Cardiovasc Electrophysiol. 2014 Oct;25(10):1057-64. doi: 10.1111/jce.12467. Epub 2014 Jul 7.
Related trials for Chronic Atrial Fibrillation
Active, not recruiting
CONVERGE Post-Approval Study (PAS)
Chronic Atrial Fibrillation
RecruitingObservational study
Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
Chronic Lymphocytic Leukemia (CLL), Waldenstr(SqrRoot)(Delta)m s Macroglobulinemia
Active, not recruitingObservational study
Vericiguat Use and Incident Atrial Fibrillation in Chronic Heart Failure
Chronic Heart Failure
Enrolling by invitationObservational study
Hypertension and Arrhythmias in CLL Patients Treated With BTK Inhibitors
Chronic Lymphocytic Leukemia, Atrial Fibrillation
Active, not recruitingObservational study
Health Electronic Assessment of Risks and Trends Using Biometric Equipment and Technology
Heart Diseases
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Andrea Natale, MD principal investigator
TCAI
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Chronic Atrial Fibrillation, run by Texas Cardiac Arrhythmia Research Foundation at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 10 Apr 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Improvement in exercise capacity and/or endothelial health (time frame: 5-6 months following catheter ablation). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01892774, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Apr 2019.